No Data
No Data
No Data
No Data
No Data
Evolus to Report First Quarter Financial Results on May 7, 2024
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2024 financial results on Tuesday, May
BusinesswireApr 24 04:30
Evolus Announces Publication Of Safety and Duration Data From Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau
The article published in Aesthetic Surgery Journal supports safety and duration of effect for temporary improvement in the appearance of moderate to severe glabellar lines presented at the 2023 ASDS A
BenzingaApr 18 04:13
AbbVie Working With FDA After Reports of Fake Botox Versions
Seeking AlphaApr 16 22:47
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
cls.cnApr 15 14:37
Evolus Insiders Sell US$3.0m Of Stock, Possibly Signalling Caution
Over the past year, many Evolus, Inc. (NASDAQ:EOLS) insiders sold a significant stake in the company which may have piqued investors' interest. When analyzing insider transactions, it is usually mor
Simply Wall StApr 14 20:53
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 9,651
BusinesswireApr 13 04:05
No Data
No Data